| Autor: |
Wahoski CC; Program in Cancer Biology, Vanderbilt University, Nashville, TN 37232, USA.; Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA., Singh B; Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA. |
| Jazyk: |
angličtina |
| Zdroj: |
Cancers [Cancers (Basel)] 2024 Jul 06; Vol. 16 (13). Date of Electronic Publication: 2024 Jul 06. |
| DOI: |
10.3390/cancers16132472 |
| Abstrakt: |
Colorectal cancer (CRC) is one of the most diagnosed cancers and a leading contributor to cancer-related deaths in the United States. Clinically, standard treatment regimens include surgery, radiation, and chemotherapy; however, there has been increasing development and clinical use of targeted therapies for CRC. Unfortunately, many patients develop resistance to these treatments. Cetuximab, the first targeted therapy approved to treat advanced CRC, is a monoclonal antibody that targets the epidermal growth factor receptor and inhibits downstream pathway activation to restrict tumor cell growth and proliferation. CRC resistance to cetuximab has been well studied, and common resistance mechanisms include constitutive signal transduction through downstream protein mutations and promotion of the epithelial-to-mesenchymal transition. While the most common resistance mechanisms are known, a proportion of patients develop resistance through unknown mechanisms. One protein predicted to contribute to therapy resistance is RAC1, a small GTPase that is involved in cytoskeleton rearrangement, cell migration, motility, and proliferation. RAC1 has also been shown to be overexpressed in CRC. Despite evidence that RAC1 and its alternative splice isoform RAC1B play important roles in CRC and the pathways known to contribute to cetuximab resistance, there is a need to directly study the relationship between RAC1 and RAC1B and cetuximab resistance. This review highlights the recent studies investigating RAC1 and RAC1B in the context of CRC and suggests that these proteins could play a role in resistance to cetuximab. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
